- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.01. | Immunovia AB: Immunovia receives state regulatory approval for PancreaSure in California and initiates commercial rollout | 105 | GlobeNewswire (Europe) | Immunovia AB (IMMNOV: Nasdaq Stockholm), a pancreatic cancer diagnostics company, today announced that it has received regulatory approval for its PancreaSure test in California, US, enabling commercial... ► Artikel lesen | |
| 17.12.25 | Immunovia AB: The Board of Directors of Immunovia proposes a reverse share split | 167 | GlobeNewswire (Europe) | The Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") proposes that an Extraordinary General Meeting on 22 January 2026 resolves to carry out a reverse share split, in the ratio... ► Artikel lesen | |
| 26.11.25 | Immunovia AB Q3 Loss Decreases | 1 | RTTNews | ||
| 26.11.25 | Immunovia: Strategiewechsel und Aktiensprung nach Q3-Zahlen | 3 | Investing.com Deutsch | ||
| 26.11.25 | Immunovia AB: Immunovia receives final Medicare payment rate for PancreaSure test | 159 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized a national payment... ► Artikel lesen | |
| 26.11.25 | Immunovia AB: Immunovia Publishes Interim Report for July-September 2025 | 155 | GlobeNewswire (Europe) | Highlights July-September 2025Net sales and operating loss for Q3 2025 in line with expectations: Net sales of 101 KSEK for the period (235) largely reflected royalty revenue. Operating loss was 25.5... ► Artikel lesen | |
| IMMUNOVIA Aktie jetzt für 0€ handeln | |||||
| 03.10.25 | Immunovia AB: Immunovia publishes information document regarding rights issue | 422 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 01.10.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 01.10.2025 | 514 | Xetra Newsboard | Das Instrument RIHN CH0003671440 RIETER HLDG NA SF 5 EQUITY wird cum Kapitalmassnahme gehandelt am 01.10.2025 und ex Kapitalmassnahme am 02.10.2025 The instrument RIHN CH0003671440 RIETER HLDG NA SF... ► Artikel lesen | |
| 29.09.25 | Immunovia AB: Bulletin from the extraordinary general meeting in Immunovia AB (publ) | 275 | GlobeNewswire (Europe) | Today, on 29 September 2025, an extraordinary general meeting was held in Immunovia AB (publ). A summary of the adopted resolutions follows below.
Resolution on amendment of the Articles of AssociationThe... ► Artikel lesen | |
| 23.09.25 | Proteomedix vereinbart Lizenzabkommen mit Immunovia | 2 | punkt4.info | ||
| 22.09.25 | Onconetix-Tochter lizenziert Biomarker-Technologie an Immunovia | 1 | Investing.com Deutsch | ||
| 22.09.25 | Onconetix, Inc.: Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM | 510 | GlobeNewswire (Europe) | CINCINNATI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the "Company") a commercial stage biotechnology company focused on the research, development and commercialization... ► Artikel lesen | |
| 22.09.25 | Immunovia AB: Immunovia Secures Control of PancreaSure Supply Chain and Achieves Cost Reduction through Licensing Agreement | 200 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia AB (publ.), the pancreatic cancer diagnostics company, has announced the successful conclusion of an agreement to acquire assets and license intellectual property that will... ► Artikel lesen | |
| 15.09.25 | Immunovia AB: Inova Schar Cancer Adopts Immunovia's PancreaSure Test for its High-Risk Surveillance Program | 209 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (publ.), the pancreatic cancer diagnostics company, today announced that its PancreaSure test will be offered to patients in Inova Schar Cancer's high-risk surveillance program... ► Artikel lesen | |
| 08.09.25 | Immunovia AB: Immunovia enters into top guarantee commitments for the upcoming rights issue | 239 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 28.08.25 | Immunovia Q2 2025 slides: PancreaSure launch plan unveiled amid stock decline | 3 | Investing.com | ||
| 28.08.25 | Immunovia-Aktie bricht nach Q2-Zahlen ein - trotz neuem Krebstest | 3 | Investing.com Deutsch | ||
| 28.08.25 | Immunovia AB: Immunovia Publishes Interim Report for January-June 2024 | 191 | GlobeNewswire (Europe) | April-June 2025Net sales, which for the quarter only included royalties, amounted to 90 KSEK (85).Operating loss was -20.1 MSEK, down from -23.9 MSEK in the second quarter of 2024. Net earnings were... ► Artikel lesen | |
| 27.08.25 | Immunovia AB: Immunovia carries out a rights issue of approximately SEK 100 million and secures bridge loans | 457 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 19.08.25 | Immunovia AB: Immunovia set to launch PancreaSure in the US on September 2nd, shares commercial strategy | 188 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (publ.) the pancreatic cancer diagnostics company, today announced that the PancreaSure test is set to launch in the US on September 2nd. The company's initial focus will be... ► Artikel lesen |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HIMS & HERS HEALTH | 24,350 | +1,42 % | Hims & Hers Scales Platform-Led Digital Healthcare Access and Care | ||
| BECTON DICKINSON | 169,20 | +0,09 % | BD (Becton, Dickinson and Company): BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases; BD Completed $250 Million Repurchase to Date in FY26 | FRANKLIN LAKES, N.J., Jan. 27, 2026 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology... ► Artikel lesen | |
| RYMAN HEALTHCARE | 1,400 | 0,00 % | Ryman Healthcare Slid To Loss In H1 | WELLINGTON (dpa-AFX) - Ryman Healthcare Ltd. (RYM.NZ), a retirement village and rest home operator, on Thursday reported loss in the first half compared with the previous year. For the half... ► Artikel lesen | |
| SOLENO THERAPEUTICS | 34,040 | -6,53 % | SOLENO THERAPEUTICS INC - 8-K, Current Report | ||
| SIENNA SENIOR LIVING | 13,100 | -0,76 % | Dividendenbekanntmachungen (31.12.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADIA REALTY TRUST US0042391096 0,2 USD 0,1702 EUR ACADIAN TIMBER CORP CA0042721005 0,29 CAD 0,1802 EUR AGNC INVESTMENT CORP US00123Q1040 0... ► Artikel lesen | |
| NIAGEN BIOSCIENCE | 4,940 | -2,18 % | Niagen Bioscience now allows HSA/FSA payments for Tru Niagen | ||
| MICROPORT SCIENTIFIC | 1,260 | -4,55 % | MICROPORT Soars ~8% on Positive Profit Alert | ||
| EXTENDICARE | 14,200 | -0,70 % | XFRA 5XE: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| VERADIGM | 4,000 | +17,65 % | Veradigm Inc. - 8-K, Current Report | ||
| NATIONAL HEALTHCARE CORPORATION | 114,00 | -0,87 % | National HealthCare Corp: Aktie klettert auf Rekordhoch von 145,04 USD | ||
| HANGZHOU TIGERMED CONSULTING | 5,400 | +4,85 % | TIGERMED (03347): ANNUAL RESULTS ESTIMATE FOR 2025 | ||
| UNIPHAR | 3,845 | +0,13 % | IN BRIEF: Uniphar says confident of reaching 2028 earnings target | ||
| AESTHETIC MEDICAL INTERNATIONAL | 0,036 | 0,00 % | Aesthetic Medical International Holdings Group Ltd - 6-K, Report of foreign issuer | ||
| FRESENIUS | 46,830 | -1,72 % | EQS-PVR: Fresenius SE & Co. KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
26.01.2026 /... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 37,450 | +0,48 % | JPMORGAN stuft FMC FRESENIUS MEDICAL CARE AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für FMC mit einem Kursziel von 37,40 Euro auf "Underweight" belassen. Analyst David Adlington nahm am Donnerstagabend in seinem... ► Artikel lesen |
IMMUNOVIA AB gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,022 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNOVIA AB finden Sie auf Wallstreet Online.